

# Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings

## A Randomized Trial

Laura A. Young, MD, PhD; John B. Buse, MD, PhD; Mark A. Weaver, PhD; Maihan B. Vu, DrPH, MPH; C. Madeline Mitchell, MURP; Tamara Blakeney, BS; Kimberlea Grimm, BAS; Jennifer Rees, RN, CPF; Franklin Niblock, BS; Katrina E. Donahue, MD, MPH; for the Monitor Trial Group

**IMPORTANCE** The value of self-monitoring of blood glucose (SMBG) levels in patients with non-insulin-treated type 2 diabetes has been debated.

**OBJECTIVE** To compare 3 approaches of SMBG for effects on hemoglobin A<sub>1c</sub> levels and health-related quality of life (HRQOL) among people with non-insulin-treated type 2 diabetes in primary care practice.

**DESIGN, SETTING, AND PARTICIPANTS** The Monitor Trial study was a pragmatic, open-label randomized trial conducted in 15 primary care practices in central North Carolina. Participants were randomized between January 2014 and July 2015. Eligible patients with type 2 non-insulin-treated diabetes were: older than 30 years, established with a primary care physician at a participating practice, had glycemic control (hemoglobin A<sub>1c</sub>) levels higher than 6.5% but lower than 9.5% within the 6 months preceding screening, as obtained from the electronic medical record, and willing to comply with the results of random assignment into a study group. Of the 1032 assessed for eligibility, 450 were randomized.

**INTERVENTIONS** No SMBG, once-daily SMBG, and once-daily SMBG with enhanced patient feedback including automatic tailored messages delivered via the meter.

**MAIN OUTCOMES AND MEASURES** Coprimary outcomes included hemoglobin A<sub>1c</sub> levels and HRQOL at 52 weeks.

**RESULTS** A total of 450 patients were randomized and 418 (92.9%) completed the final visit. There were no significant differences in hemoglobin A<sub>1c</sub> levels across all 3 groups ( $P = .74$ ; estimated adjusted mean hemoglobin A<sub>1c</sub> difference, SMBG with messaging vs no SMBG,  $-0.09\%$ ; 95% CI,  $-0.31\%$  to  $0.14\%$ ; SMBG vs no SMBG,  $-0.05\%$ ; 95% CI,  $-0.27\%$  to  $0.17\%$ ). There were also no significant differences found in HRQOL. There were no notable differences in key adverse events including hypoglycemia frequency, health care utilization, or insulin initiation.

**CONCLUSIONS AND RELEVANCE** In patients with non-insulin-treated type 2 diabetes, we observed no clinically or statistically significant differences at 1 year in glycemic control or HRQOL between patients who performed SMBG compared with those who did not perform SMBG. The addition of this type of tailored feedback provided through messaging via a meter did not provide any advantage in glycemic control.

**TRIAL REGISTRATION** clinicaltrials.gov Identifier: [NCT02033499](https://clinicaltrials.gov/ct2/show/study/NCT02033499)

JAMA Intern Med. 2017;177(7):920-929. doi:10.1001/jamainternmed.2017.1233  
Published online June 10, 2017. Corrected on August 7, 2017.

← Editor's Note [page 929](#)

+ Author Video Interview and JAMA Report Video

+ Supplemental content

+ CME Quiz at [jamanetwork.com/learning](http://jamanetwork.com/learning)

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Group Information:** A complete list of the Monitor Trial Group members is provided in at the end of the article.

**Corresponding Author:** Katrina Donahue, MD, MPH, Department of Family Medicine, School of Medicine, University of North Carolina at Chapel Hill, CB #7595, 590 Manning Dr, Chapel Hill, NC 27599-7595 ([kdonahue@med.unc.edu](mailto:kdonahue@med.unc.edu)).

The value of self-monitoring of blood glucose (SMBG) for patients with non-insulin-treated type 2 diabetes mellitus (T2DM) has been debated,<sup>1-7</sup> yet over 75% perform regular SMBG.<sup>8</sup> Several trials showed significant benefit from SMBG on glycemic control,<sup>9-12</sup> while others found no evidence of benefit.<sup>7,13-16</sup> Proponents postulate that testing promotes better awareness of glucose levels, leading to improvements in diet and lifestyle. However, harms from routine SMBG in patients with non-insulin-treated T2DM are possible.<sup>17,18</sup>

Studies of enhanced SMBG, where patients and/or clinicians were educated to better interpret SMBG values, found hemoglobin A<sub>1c</sub> reductions close to 0.5%,<sup>3,10,19,20</sup> compared with simple SMBG, where levels were reduced by 0.2%, an amount that was statistically significant but of doubtful clinical significance.<sup>3,21</sup> This pattern suggests that, for SMBG to be an effective self-management tool in non-insulin-treated T2DM, the patient and physician must actively engage in performing, interpreting, and acting on the SMBG values.

Our goal was to answer the following question: Is SMBG effective for people with non-insulin-treated T2DM in terms of improving either hemoglobin A<sub>1c</sub> levels or health-related quality of life (HRQOL)?

## Methods

### Trial Design

We performed this pragmatic trial across 15 primary care practices in central North Carolina. The trial was funded by the Patient-Centered Outcomes Research Institute Diabetes stakeholders provided input during grant design, implementation, and dissemination.<sup>22</sup> The trial protocol (Supplement 1) was reviewed and approved by the University of North Carolina institutional review board. Written informed consent was obtained and participants were compensated with \$50 for filling out baseline and follow-up surveys. Participants in the testing arms also received a meter and test strips. Patients with non-insulin-treated T2DM were randomly assigned to 1 of 3 arms: (1) no SMBG; (2) standard once-daily SMBG consisting of glucose values immediately reported to the patient through the meter; and (3) enhanced once-daily SMBG consisting of glucose values immediately reported to the patient plus automated, tailored messaging delivered to the patient through a Telcare meter. The messaging algorithm accounted for blood glucose value, time of day, and relationship to food intake. Messages were intended to educate and motivate patients (eTable 2 in Supplement 2). Time- and date-stamped data uploaded from the meters allowed the study team to monitor daily meter use in the SMBG arms. Following randomization, primary care clinicians guided participants' routine diabetes management. Clinicians received summaries of SMBG data and potential treatment options based on American Diabetes Association Standards of Care<sup>1</sup> through the electronic health record for patients in both testing arms. The recommendations were not prescriptive and clinicians were encouraged to use them based on clinical situation. Participants were reassessed at 52 weeks following randomization.

### Key Points

**Question** Is self-monitoring blood glucose levels effective for people with non-insulin-treated type 2 diabetes in terms of improving either hemoglobin A<sub>1c</sub> levels or health-related quality of life (HRQOL) in primary care practice?

**Findings** In this pragmatic randomized clinical trial that included 450 patients randomized to 1 of 3 groups: no self-monitoring of blood glucose (SMBG), once-daily SMBG, and once-daily SMBG with enhanced patient feedback. There were no significant differences in glycemic control across all groups, nor were there significant differences found in HRQOL.

**Meaning** Routine self-monitoring of blood glucose levels does not significantly improve hemoglobin A<sub>1c</sub> levels or HRQOL for most patients with non-insulin-treated type 2 diabetes; patients and clinicians should consider the specifics of each clinical situation as they decide whether to test or not to test.

### Patients

Eligibility criteria included: (1) T2DM, (2) 30 years or older, (3) established patient at a participating practice, (4) hemoglobin A<sub>1c</sub> levels between 6.5% and 9.5% within 6 months preceding screening, and (5) willing to be randomly assigned to a study group. Patients were excluded if they planned to see an endocrinologist in the upcoming year, currently or planned to use insulin during study period, planned to become pregnant or relocate in the next year, or had other conditions that would put them at risk in following study protocol. Patients were not excluded if they had prior SMBG experience.


### Baseline Procedures

After study field staff obtained written informed consent, patients completed an interview that included demographic, health history, and patient-reported measures. Patients had a hemoglobin A<sub>1c</sub> blood test and height and weight were recorded. The field coordinator then opened a numbered, opaque randomization envelope containing group assignment. Randomization was stratified by practice and used randomly permuted blocks of sizes 15 and 18 generated by a biostatistics research assistant not otherwise involved in the study. The field coordinator taught patients randomized to the testing groups how to use the meter. All participants received educational brochures describing blood glucose goals and symptoms of hypoglycemia and hyperglycemia.

### Outcomes

The 2 primary outcomes were change in hemoglobin A<sub>1c</sub> levels and in HRQOL. Hemoglobin A<sub>1c</sub> levels were measured at baseline and again at a mean (SD) 52 (6) weeks from baseline visit. For the first 40 patients enrolled, baseline hemoglobin A<sub>1c</sub> levels were measured by total glycosylated hemoglobin; glycosylated hemoglobin was calculated using a published formula by the processing laboratory. The remainder of patients had their hemoglobin A<sub>1c</sub> levels measured by glycosylated hemoglobin by a single laboratory at baseline and follow up visits. Intermediate hemoglobin A<sub>1c</sub> values were captured passively from the electronic health record. We assessed HRQOL

Figure 1. The Monitor Trial CONSORT Flow Diagram



using physical and mental component scores of the Short-Form 36 (SF-36).<sup>23</sup> Secondary outcomes included Problem Areas In Diabetes,<sup>24</sup> Diabetes Symptoms Checklist,<sup>25</sup> and Diabetes Empowerment Scale<sup>26</sup> to assess diabetes-specific HRQOL and self-efficacy. We examined diabetes self-care through the Summary of Diabetes Self-Care Activities measure.<sup>27</sup> Treatment satisfaction and provider-patient communication were assessed through the Diabetes Treatment Satisfaction Questionnaire<sup>28</sup> and the Communication Assessment Tool.<sup>29</sup>

Preidentified potentially study-related adverse events (AEs) included finger stick infections and severe hypoglycemia. Emergency department and hospitalizations alerts from the electronic health record allowed review of intrastudy events, which were adjudicated by committee. At follow-up, participants were queried regarding any urgent care, emergency department visit, hospitalization, finger stick infection, and hypoglycemic episode over the past 52 weeks.

**Statistical Analysis**

We calculated power for the 2 *df* overall tests comparing our primary outcomes across all 3 groups. Assuming a common standard deviation for change in hemoglobin A<sub>1c</sub> levels of 0.8% and no more than 10% loss to follow-up, randomizing 150 patients per group would provide at least 90% power to detect a mean difference of -0.325% between the SMBG and no SMBG groups at the .05 significance level. Assuming a HRQOL standard deviation of 10 points, this sample size would provide at least 80% power to detect an overall difference between groups if the mean difference between the highest and lowest groups

was at least 4 points on either component of the HRQOL scale at the .025 level (Bonferroni-corrected for 2 components).

For primary analyses, all randomized patients were analyzed according to their group regardless of the extent to which they performed SMBG (intention-to-treat, ITT). The statistician remained blinded to treatment groups until after finalization of programming for primary comparisons. Missing 52-week outcome data were ignored for primary analyses. We compared change in hemoglobin A<sub>1c</sub> levels from baseline through 52 weeks across the 3 randomization groups using an analysis of covariance (ANCOVA) conducted at the .05 significance level. This model controlled for site, baseline hemoglobin A<sub>1c</sub> levels, whether baseline hemoglobin A<sub>1c</sub> levels were directly measured or calculated, use of SMBG at baseline, duration of diabetes, baseline use of antihyperglycemic treatment (sulfonylurea or glinide), age, race/ethnicity, health literacy, and number of comorbidities. Had the overall test been rejected, we planned to compare each SMBG group to the no testing group separately using the Dunnett-Tamhane Step-Up procedure.<sup>30</sup> We also conducted a contrast test comparing the average of the 2 SMBG groups to the no SMBG group at the .05 level. ANCOVA similar models were used to compare groups for change in HRQOL component scores as well as listed secondary outcomes; besides the covariates listed above, each of these models controlled for corresponding baseline scale score. Additionally, we explored potential for effect modification by each baseline variable included in the models by adding appropriate interaction terms to the ANCOVA model 1 at a time.

We conducted 3 prespecified sensitivity analyses for the hemoglobin A<sub>1c</sub> comparison. First, we repeated ITT analysis using

Table 1. Baseline Characteristics

| Characteristic                             | Randomization Group  |                                    |                                     | Total<br>(n = 450) |
|--|----------------------|------------------------------------|-------------------------------------|--------------------|
|  | No SMBG<br>(n = 152) | SMBG,<br>No Messaging<br>(n = 150) | SMBG With<br>Messaging<br>(n = 148) |                    |
| Age, median (range), y                     | 61 (31-89)           | 63 (32-82)                         | 61 (35-92)                          | 61 (31-92)         |
| Sex, No. (%)                               |                      |                                    |                                     |                    |
| Male                                       | 74 (48.7)            | 67 (44.7)                          | 66 (44.6)                           | 207 (46.0)         |
| Female                                     | 78 (51.3)            | 83 (55.3)                          | 82 (55.4)                           | 243 (54.0)         |
| Race, No. (%)                              |                      |                                    |                                     |                    |
| Black                                      | 42 (27.6)            | 55 (36.7)                          | 51 (34.5)                           | 148 (32.9)         |
| White                                      | 104 (68.4)           | 89 (59.3)                          | 86 (58.1)                           | 279 (62.0)         |
| Other                                      | 6 (3.9)              | 6 (4.0)                            | 11 (7.4)                            | 23 (5.1)           |
| Ethnicity, non-Latino Hispanic, No. (%)    | 148 (97.4)           | 147 (98.7)                         | 146 (98.6)                          | 441 (98.2)         |
| Education, No. (%)                         |                      |                                    |                                     |                    |
| <High school                               | 6 (4.0)              | 10 (6.7)                           | 9 (6.1)                             | 25 (5.6)           |
| High school/some college                   | 95 (62.9)            | 87 (58.0)                          | 89 (60.1)                           | 271 (60.4)         |
| College or higher                          | 50 (33.1)            | 53 (35.3)                          | 50 (33.8)                           | 153 (34.1)         |
| BMI, median (range)                        | 33 (22-58)           | 33 (21-62)                         | 34 (21-75)                          | 33 (21-75)         |
| Low health literacy, No. (%) <sup>a</sup>  | 62 (40.8)            | 54 (36.5)                          | 55 (37.2)                           | 171 (38.2)         |
| Years with diabetes, median (range)        | 6 (0-45)             | 6 (0-44)                           | 6 (0-50)                            | 6 (0-50)           |
| Diabetes 1 y or less, No. (%)              | 25 (16.4)            | 27 (18.0)                          | 14 (9.5)                            | 66 (14.7)          |
| No. of comorbidities, median (range)       | 3 (0-9)              | 3 (0-10)                           | 3 (0-8)                             | 3 (0-10)           |
| Use of SMBG, No. (%)                       |                      |                                    |                                     |                    |
| Current                                    | 114 (75.0)           | 108 (72.0)                         | 116 (78.4)                          | 338 (75.1)         |
| Ever                                       | 138 (90.8)           | 135 (90.0)                         | 143 (96.6)                          | 416 (92.4)         |
| Testing preference, No. (%)                |                      |                                    |                                     |                    |
| Any SMBG                                   | 63 (41.4)            | 56 (37.3)                          | 59 (39.9)                           | 178 (39.6)         |
| No SMBG                                    | 31 (20.4)            | 34 (22.7)                          | 32 (21.6)                           | 97 (21.6)          |
| Uncertain                                  | 2 (1.3)              | 1 (0.7)                            | 1 (0.7)                             | 4 (0.9)            |
| No preference                              | 56 (36.8)            | 59 (39.3)                          | 56 (37.8)                           | 171 (38.0)         |
| Diabetes medications, No. (%) <sup>b</sup> |                      |                                    |                                     |                    |
| Metformin                                  | 123 (80.9)           | 115 (76.7)                         | 120 (81.1)                          | 358 (79.6)         |
| Sulfonylurea or glinide                    | 51 (33.6)            | 50 (33.3)                          | 60 (40.5)                           | 161 (35.8)         |
| Thiazolidinedione                          | 8 (5.3)              | 3 (2.0)                            | 10 (6.8)                            | 21 (4.7)           |
| GLP-1 agonist                              | 5 (3.3)              | 2 (1.3)                            | 10 (6.8)                            | 17 (3.8)           |
| DPP-4 inhibitor                            | 12 (7.9)             | 11 (7.3)                           | 17 (11.5)                           | 40 (8.9)           |

Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); SMBG, self-monitoring of blood glucose.

<sup>a</sup> Scoring less than 4 on Newest Vital Sign.<sup>31</sup>

<sup>b</sup> Other diabetes medications were less than 5%.

a per-protocol population that excluded participants who initiated insulin use during the study or who were not sufficiently compliant with their assigned treatment. In the testing arms, we excluded participants who uploaded a meter reading fewer than 80% of their days in the study, and in the no testing arm we excluded participants who admitted to ever testing with any regularity during the study. Second, we repeated the ANCOVA model using linear mixed models that included all intermediate hemoglobin A<sub>1c</sub> values captured from the electronic health record, excluding any following initiation of insulin use. This model included fixed effects for linear and quadratic time trends and time-by-treatment group interactions, as well as random intercepts and slopes for each patient. As a final sensitivity analysis, we used last observation carried forward to impute the 52-week hemoglobin A<sub>1c</sub> value for any patient who was lost to follow-up or who initiated insulin during the study.

## Results

### Overview of Trial Conduct

A total of 450 patients underwent randomization from January 2014 to July 2015 (Figure 1). A total of 92.9% of patients completed the final visit and provided data on both outcomes (hemoglobin A<sub>1c</sub> levels and HRQOL). The demographic and clinical characteristics were similar among groups (Table 1). The mean age was 61 years old, patients had diabetes an average of 8 years, 75% were performing SMBG at baseline, and 38% had low health literacy (less than 4 on the Newest Vital Sign).<sup>31</sup> Patient testing preference at baseline was similar among groups with 22% preferring no SMBG and 40% preferring to self-monitor. The majority were taking metformin (80%), followed by sulphonylurea (35%).

Table 2. Summary of Primary Outcomes by Randomization Group

| Variable                                    | Randomization Group |  |                    |   |                     |   | P Value              | Contrast <sup>b</sup> |
|---|---------------------|--|--------------------|---|---------------------|---|----------------------|-----------------------|
|   | No SMBG             |  | SMBG, No Messaging |   | SMBG With Messaging |   |                      |                       |
|   | No.                 | Mean (SD)                                  | No.                | Mean (SD)                                   | No.                 | Mean (SD)                                   | Overall <sup>a</sup> |                       |
| Hemoglobin A <sub>1c</sub> , % <sup>c</sup> |                     |  |                    |   |                     |   |                      |                       |
| Baseline                                    | 152                 | 7.52 (1.12)<br>(58.70 [12.24]<br>mmol/mol) | 150                | 7.55 (1.10)<br>(59.06 [12.07]<br>mmol/mol)  | 148                 | 7.61 (0.97)<br>(59.65 [10.64]<br>mmol/mol)  | .74                  | .48                   |
| Follow-up                                   | 147                 | 7.55 (1.24)<br>(59.01 [13.56]<br>mmol/mol) | 141                | 7.49 (1.12)<br>(58.41 [12.23]<br>mmol/mol)  | 139                 | 7.51 (1.13)<br>(58.55 [12.34]<br>mmol/mol)  |                      |                       |
| Change                                      | 147                 | 0.04 (1.12)<br>(0.41 [12.27]<br>mmol/mol)  | 141                | -0.05 (1.00)<br>(-0.57 [10.89]<br>mmol/mol) | 139                 | -0.10 (1.14)<br>(-1.04 [12.42]<br>mmol/mol) |                      |                       |
| Health-Related Quality of Life, SF-36       |                     |  |                    |   |                     |   |                      |                       |
| Physical score                              |                     |  |                    |   |                     |   |                      |                       |
| Baseline                                    | 152                 | 48.72 (8.00)                               | 150                | 47.27 (8.40)                                | 148                 | 46.22 (10.13)                               | .48                  | .50                   |
| Follow-up                                   | 143                 | 48.47 (7.21)                               | 142                | 47.42 (9.03)                                | 135                 | 46.44 (9.68)                                |                      |                       |
| Change                                      | 143                 | -0.43 (6.86)                               | 142                | 0.07 (6.77)                                 | 135                 | -0.35 (6.95)                                |                      |                       |
| Mental score                                |                     |  |                    |   |                     |   |                      |                       |
| Baseline                                    | 152                 | 53.52 (9.29)                               | 150                | 52.94 (8.77)                                | 148                 | 53.43 (9.58)                                | .90                  | >.99                  |
| Follow-up                                   | 143                 | 53.39 (10.55)                              | 142                | 52.04 (9.57)                                | 135                 | 52.57 (10.39)                               |                      |                       |
| Change                                      | 143                 | -0.94 (7.46)                               | 142                | -0.71 (7.72)                                | 135                 | -1.39 (6.85)                                |                      |                       |

Abbreviation: SMBG, self-monitoring of blood glucose.

SI conversion factor: To convert percent of total hemoglobin to proportion of total hemoglobin, multiply by .01.

<sup>a</sup> Test comparing all 3 groups from ANCOVA model controlling for site, baseline hemoglobin A<sub>1c</sub>, prior use of SMBG, duration of T2DM, baseline anti-hyperglycemic treatment, age, race/ethnicity, health literacy, and number

of baseline comorbidities; for health-related quality of life scores, we also controlled for baseline score, and for hemoglobin A<sub>1c</sub> we also controlled for how hemoglobin A<sub>1c</sub> was measured at baseline.

<sup>b</sup> Contrast test from same ANCOVA model comparing average of SMBG groups with no SMBG group.

<sup>c</sup> Dual reported as percentage and as mmol/mol.

### Primary Outcomes

At 1 year, we found no evidence that SMBG led to improved glycemic control (estimated adjusted mean hemoglobin A<sub>1c</sub> difference: SMBG with messaging vs no SMBG, -0.09%; 95% CI, -0.31% to 0.14%; SMBG vs no SMBG, -0.05%; 95% CI, -0.27% to 0.17%; average over SMBG arms vs no SMBG, -0.07%; 95% CI, -0.26% to 0.12%) (Table 2). There were also no significant differences found in HRQOL (estimated adjusted mean difference for SF-36 Physical score: SMBG with messaging vs no SMBG, -0.83 points; 95% CI, -2.33 to 0.67; SMBG vs no SMBG, -0.05 points; 95% CI, -1.54 to 1.44; average over SMBG arms vs no SMBG, -0.44 points; 95% CI, -1.73 to 0.85; estimated adjusted mean difference for SF-36 Mental score: SMBG with messaging vs no SMBG, -0.19 points; 95% CI, -1.82 to 1.44; SMBG vs no SMBG, 0.19 points; 95% CI, -1.43 to 1.81; average over SMBG arms vs no SMBG, 0 points; 95% CI, -1.40 to 1.40).

### Secondary Outcomes

We did not find significant differences in patient-reported outcomes by the Problem Areas in Diabetes, Diabetes Symptom Checklist, Diabetes Empowerment Scale, Diabetes Treatment Satisfaction, or the Communication Assessment Tool (Table 3). There were significant differences in the Summary of Diabetes Self-Care Activities (mean change 0.01 points, 0.51 points, and 0.45 points, in the no SMBG, SMBG, and SMBG with messaging, respectively; overall,  $P < .001$ ). However, this was owing to the influence of the SMBG intervention (blood glucose testing subscale mean change, -1.46 points, 2.94 points, 2.81 points in the no SMBG, SMBG, and SMBG with messaging, respectively; overall,  $P < .001$ ). Among the arms, there were

no significant differences in insulin initiation (8.6%, 4.0%, 5.4% in the no SMBG, SMBG, SMBG with messaging, respectively; overall,  $P = .23$ ). Patients in the SMBG groups taking a GLP-1 agonist at baseline were significantly more likely to increase their dose compared with patients in the no SMBG group ( $P = .02$ ), but the numbers were small (eTable 1 in Supplement 2). In addition, patients in the SMBG with messaging group were significantly more likely to start using thiazolidinedione ( $P = .01$ ), but again the numbers were small. No other comparisons of medication use differed significantly between groups.

### Sensitivity Analyses

In per-protocol and last observation carried forward analyses, results were not notably different from those in the primary analyses. We did find evidence that mean hemoglobin A<sub>1c</sub> values differed across groups over time. At 6 months, the estimated mean hemoglobin A<sub>1c</sub> difference between the testing arms and the no testing arm was -0.33% (95% CI, -0.54% to -0.12%;  $P = .002$ ). By 12 months, the mean differences between groups are similar to the primary analysis and do not show a significant difference. (Figure 2A).

### Effect Modification

In analyses exploring potential for effect modification of pre-specified subgroups (prior experience using SMBG, T2DM duration, baseline glycemic control, baseline insulin secretagogue use, age, race/ethnicity, health literacy, and number of baseline comorbidities), there were no significant interactions for glycemic control. For the HRQOL physical compo-

Table 3. Secondary Outcomes by Randomization Group Diabetes Mellitus Patient-Reported Outcomes

| Variable  | Randomization Group |               |                    |               |                     |               | P Value              |                       |
|---|---------------------|---------------|--------------------|---------------|---------------------|---------------|----------------------|-----------------------|
|   | No SMBG             |               | SMBG, No Messaging |               | SMBG With Messaging |               | Overall <sup>a</sup> | Contrast <sup>b</sup> |
|   | No.                 | Mean (SD)     | No.                | Mean (SD)     | No.                 | Mean (SD)     |                      |                       |
| Problem areas in diabetes (PAID)                                |                     |               |                    |               |                     |               |                      |                       |
| Baseline  | 152                 | 13.12 (15.53) | 150                | 12.54 (14.89) | 148                 | 13.67 (18.16) | .21                  | .08                   |
| Follow-up   | 143                 | 11.06 (15.45) | 142                | 8.96 (13.90)  | 135                 | 9.04 (14.54)  |                      |                       |
| Change  | 143                 | -1.97 (15.44) | 142                | -4.01 (12.16) | 135                 | -3.84 (13.53) |                      |                       |
| Diabetes symptoms checklist (DSC)                               |                     |               |                    |               |                     |               |                      |                       |
| Baseline  | 152                 | 19.04 (19.56) | 150                | 21.55 (21.88) | 148                 | 20.73 (22.62) | .06                  | .06                   |
| Follow-up   | 143                 | 21.43 (23.73) | 142                | 19.46 (20.10) | 135                 | 19.80 (21.42) |                      |                       |
| Change  | 143                 | 2.15 (14.37)  | 142                | -2.36 (15.37) | 135                 | 0.53 (14.78)  |                      |                       |
| Diabetes empowerment scale (DES-SF)                             |                     |               |                    |               |                     |               |                      |                       |
| Baseline  | 152                 | 4.35 (0.48)   | 149                | 4.33 (0.50)   | 148                 | 4.27 (0.58)   | .28                  | .28                   |
| Follow-up   | 143                 | 4.43 (0.49)   | 142                | 4.42 (0.47)   | 135                 | 4.46 (0.49)   |                      |                       |
| Change  | 143                 | 0.08 (0.53)   | 141                | 0.11 (0.50)   | 135                 | 0.20 (0.49)   |                      |                       |
| Summary of diabetes self-care activities (total score)          |                     |               |                    |               |                     |               |                      |                       |
| Baseline  | 152                 | 3.42 (1.32)   | 150                | 3.64 (1.42)   | 148                 | 3.46 (1.34)   | <.001                | <.001                 |
| Follow-up   | 143                 | 3.39 (1.23)   | 142                | 4.12 (1.30)   | 135                 | 3.87 (1.32)   |                      |                       |
| Change  | 143                 | 0.01 (1.00)   | 142                | 0.51 (1.14)   | 135                 | 0.45 (1.67)   |                      |                       |
| Summary of diabetes self-care activities (blood sugar subscale) |                     |               |                    |               |                     |               |                      |                       |
| Baseline  | 152                 | 2.54 (2.62)   | 149                | 2.65 (2.77)   | 148                 | 2.64 (2.87)   | <.001                | <.001                 |
| Follow-up   | 143                 | 0.95 (2.00)   | 142                | 5.60 (2.29)   | 135                 | 5.39 (2.30)   |                      |                       |
| Change  | 143                 | -1.46 (2.83)  | 141                | 2.94 (3.23)   | 135                 | 2.81 (3.30)   |                      |                       |
| Diabetes Treatment Satisfaction                                 |                     |               |                    |               |                     |               |                      |                       |
| Baseline  | 149                 | 31.74 (5.52)  | 147                | 31.71 (4.92)  | 148                 | 31.89 (4.96)  | .48                  | .48                   |
| Follow-up   | 135                 | 31.66 (6.27)  | 141                | 32.21 (4.89)  | 135                 | 31.74 (5.90)  |                      |                       |
| Change  | 133                 | -0.16 (6.26)  | 138                | 0.67 (4.95)   | 135                 | -0.28 (5.89)  |                      |                       |
| Communication assessment tool                                   |                     |               |                    |               |                     |               |                      |                       |
| Baseline  | 152                 | 4.53 (0.69)   | 150                | 4.35 (0.70)   | 148                 | 4.49 (0.76)   | .68                  | .45                   |
| Follow-up   | 141                 | 4.57 (0.68)   | 142                | 4.52 (0.74)   | 134                 | 4.53 (0.71)   |                      |                       |
| Change  | 141                 | 0.03 (0.68)   | 142                | -0.02 (0.65)  | 134                 | 0.01 (0.75)   |                      |                       |

Abbreviation: SMBG, self-monitoring of blood glucose.

<sup>a</sup> Test comparing all 3 groups from ANCOVA model controlling for site, baseline scale score, baseline hemoglobin A<sub>1c</sub>, prior use of SMBG, duration of T2DM, baseline antihyperglycemic treatment, age, race/ethnicity, health literacy, and

number of baseline comorbidities.

<sup>b</sup> Contrast test from same ANCOVA model comparing average of testing groups with no testing group.

ment score, we did identify a significant interaction by race ( $P = .02$ ); African Americans in the SMBG with messaging group reported significantly lower HRQOL than the no testing group, but the same was not true for the SMBG without messaging group (estimated adjusted mean differences of SF-36 physical component score for African Americans: SMBG with messaging vs no SMBG, -2.91 points; 95% CI, -5.69 to -0.13; SMBG vs no SMBG, 0.78 points; 95% CI, -1.91 to 3.47) (eFigures 1-3 in Supplement 2).


### Testing Compliance

Compliance dropped consistently in both SMBG groups, with a larger initial decrease after 1 month in the SMBG with mes-

saging arm (Figure 2B). In the no SMBG arm, 36 (23.7%) patients reported that they tested a few times per month or more, 2 (1%) tested once per month, and 13 (8.5%) tested less than once per month during the study.

### Safety and Adverse Events

The following adverse events occurred during the study: 0 fingerstick infections, 1 severe hypoglycemia (secondary to urosepsis, recurrent bladder neoplasm, and acute kidney injury), 62 hospitalizations (no difference by arm), and 2 deaths (1 during cardiac surgery and 1 owing to amyotrophic laterals sclerosis). None of the adverse events were adjudicated to be study-related.

Figure 2. Mean Hemoglobin A<sub>1c</sub> by Study Arm Over Time and Daily Proportions of Patients Testing in the SMBG Groups

A, Model-estimated mean hemoglobin A<sub>1c</sub> values obtained by fitting a quadratic polynomial regression with linear mixed models using all observed hemoglobin A<sub>1c</sub> values, including those at interim visits, but excluding any following insulin use. The model included 1875 total hemoglobin A<sub>1c</sub> measurements from 450 patients; only 10 patients contributed no interim hemoglobin A<sub>1c</sub> measurements and the median number was 4. The intervals represent

pointwise 95% CIs for each group, and the *P* values compare the average of the SMBG groups with the no SMBG group. B, Daily proportions of patients in the SMBG groups uploading a result with the meter on each study day. Lines represent locally weighted smoothing using local quadratic polynomials across the observed proportions. SMBG indicates self-monitoring of blood glucose.

## Discussion

After 1 year, we identified no clinically or statistically significant differences in glycemic control or HRQOL between patients who performed once-daily SMBG compared with those who did not perform SMBG. The addition of instant tailored feedback messages via a meter did not improve glycemic control. This null result occurred despite training participants and primary care clinicians on the use and interpretation of the meter results. These findings align with earlier studies and a group that reinforce the limited utility of SMBG in patients with non-insulin-treated T2DM.<sup>4,5,7,13-16,32</sup> Surprisingly, SMBG has remained a cornerstone in the clinical management of non-insulin-treated T2DM, in part fueled by other studies and groups supporting glycemic control with SMBG.<sup>9-12,33-35</sup> As the first large pragmatic US trial of SMBG, our findings provide evidence to guide patients and clinicians making important clinical decisions about routine blood glucose monitoring. Health care clinicians are typically divided on this issue; most universally either do or do not recommend SMBG monitoring.<sup>1,32</sup> In addition, patient testing preferences are variable; in our study, patient testing preference at baseline was split. Based on these findings, patients and clinicians should engage in dialogue regarding SMBG with the current evidence suggesting that SMBG should not be routine for most patients with non-insulin-treated T2DM. Our study was not powered to determine effectiveness in certain clinical situations, such as initiation of new medication or medication dose changes. Patients and clinicians should consider each situation as they determine whether to test or not to test.

Patients were drawn from primary care practices; where most patients with T2DM receive their care. Most were on uncomplicated medical therapies including metformin (80%) and

sulphonylureas (36%) and carried the diagnosis of T2DM for a median of 6 years. Given that only 66 (15%) patients had T2DM for a year or less, it is not surprising that most were experienced with SMBG (338, 75%) at baseline. In addition, compliance with testing showed progressive attrition in both SMBG monitoring groups. Although not a primary outcome, this may explain the statistically significant improvements in hemoglobin A<sub>1c</sub> levels initially seen between the testing and non-testing arms in the early months, but no significance at the primary outcome of 12 months. It is possible that the intervention was off putting in some way causing user fatigue or provided false reassurance.

Proponents of routine SMBG have cited evidence that this testing approach is useful for patients with newly diagnosed diabetes or patients with poorer glycemic control.<sup>10</sup> Although disease duration, experience using SMBG, baseline glycemic control, antihyperglycemic treatment, age, race, health literacy, and number of comorbidities made no discernable difference in glycemic control at 52 weeks, absence of evidence is not evidence of absence. This trial was not powered for secondary analyses. Only race was significant by interaction testing for HRQOL physical component score; African Americans in the SMBG with messaging group had significantly lower scores. Given multiple comparisons across groups, the finding may be spurious.

Incorporating technology into self-management activities has been touted as potentially transformative for patients, and to date some smaller studies<sup>36,37</sup> support this notion. However, our findings do not. It is possible that the enhancement of SMBG with one-way messaging back to the patient does not adequately engage patients. This notion is supported by the sensitivity analyses that showed that over the first 6 months glycemic control improved for all patients engaging in SMBG regardless of messaging type. However, dur-

ing months 6 through 12, improvements in glycemic control regressed back to baseline. A more interactive approach or the use of 2-way messaging between the patient and physician may improve the durability of this approach.

Although designed with an eye toward the real-world clinical setting, our study team did not engage with the patients beyond the baseline visit. Clinicians likewise had minimal interaction with the study team. Thus, we do not have data on what the clinicians did with the summary of blood glucose results. More active engagement of both patients and clinicians may have improved patient outcomes, although this would have diminished the pragmatic nature of this study. Most (338, 75%) patients had some experience with SMBG at baseline and 161 (36%) were taking oral hypoglycemics. Prior trials of SMBG were heterogeneous; many did not describe SMBG use at baseline.

### Limitations

Although our resultant population is more of a test of continuing monitoring, rather than initiating monitoring, the question remains equally relevant. The population included were willing to be randomized; this may not reflect the typical popu-

lation of patients with T2DM. In addition, not all patients adhered to the group to which they were assigned; however, per-protocol analyses were not notably different from the intent-to-treat analyses. There is also a possibility that those participating might be generally good at self-care, so an automated system may add less than in other populations. Because our population included patients with T2DM not using insulin, these results cannot be generalized to insulin users. Furthermore, participating primary care practices were affiliated with a single health care system, though patients were typical of those found in primary care nationally.<sup>38</sup>

### Conclusions

In patients with non-insulin-treated T2DM, there were no clinically or statistically significant differences at 1 year in glycemic control or HRQOL between patients who performed SMBG compared with those who did not perform SMBG. These findings suggest that glucose monitoring in patients with non-insulin-treated T2DM should not be routine.

#### ARTICLE INFORMATION

**Published Online:** June 10, 2017.

doi:10.1001/jamainternmed.2017.1233

**Correction:** This article was corrected for clarification on reporting of hemoglobin A<sub>1c</sub> in Table 2. The units of measure being reported have been more clearly labeled. The correction was made online on August 7, 2017.

**Author Affiliations:** Division of Endocrinology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (Young, Buse); Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill (Young, Mitchell, Blakeney, Grimm, Rees, Donahue); Departments of Medicine and Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (Weaver); Center for Health Promotion and Disease Prevention, UNC Chapel Hill, North Carolina (Vu); School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (Niblock); Department of Family Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (Donahue).

**Author Contributions:** Drs Donahue and Young had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Young, Buse, Weaver, Donahue.

**Acquisition, analysis, or interpretation of data:** All authors.

**Drafting of the manuscript:** Young, Weaver, Vu, Grimm, Donahue.

**Critical revision of the manuscript for important intellectual content:** Young, Buse, Weaver, Mitchell, Blakeney, Rees, Niblock, Donahue.

**Statistical analysis:** Weaver.

**Obtained funding:** Young, Donahue.

**Administrative, technical, or material support:** Buse, Mitchell, Blakeney, Grimm, Rees, Niblock.

**Study supervision:** Young, Mitchell.

**Conflict of Interest Disclosures:** Dr Young reports grants from Eli Lilly, grants from Bristol-Myers

Squibb, grants and other from GI Dynamics, grants from PhaseBio, grants from Medtronic Minimed, grants from Sanofi, grants from TolereX, grants from Halozyme, grants from Johnson & Johnson, grants from Andromeda, grants from Boehringer-Ingelheim, grants from GlaxoSmithKline, grants from Intarcia Therapeutics, grants from Lexicon, grants from Scion NeuroStim, grants from Orexigen, grants from Takeda, grants from Theracos, grants from Novo Nordisk, other from Dexcom, outside the submitted work; she is a member of the planning committee for Taking Control of Your Diabetes; and UNC has licensed its interest in copyright works to Telcare of a glucose messaging and treatment algorithm for the purposes of commercialization. Dr Buse reports grants, nonfinancial support, and other from Eli Lilly, grants, nonfinancial support, and other from Bristol-Myers Squibb, grants, nonfinancial support, and other from GI Dynamics, nonfinancial support and other from Elcylex, grants, nonfinancial support, and other from Merck, nonfinancial support and other from Metavention, nonfinancial support and other from vTv Pharma, grants, personal fees, nonfinancial support, and other from PhaseBio, grants, nonfinancial support, and other from AstraZeneca, nonfinancial support and other from Dance Biopharm, nonfinancial support and other from Quest, grants from Medtronic Minimed, grants, nonfinancial support, and other from Sanofi, grants from TolereX, grants from Osiris, grants from Halozyme, grants from Johnson & Johnson, grants from Andromeda, grants from Boehringer-Ingelheim, grants from GlaxoSmithKline, grants from Astellas, grants from MacroGenics, grants from Intarcia Therapeutics, grants, nonfinancial support, and other from Lexicon, grants from Scion NeuroStim, grants, nonfinancial support, and other from Orexigen, grants, nonfinancial support, and other from Takeda, nonfinancial support and other from Adocia, grants, nonfinancial support, and other from F. Hoffman LaRoche, grants from Theracos, grants, nonfinancial support, and other from Novo Nordisk outside the submitted work; and he is or has been a member of a variety of

nonprofit boards: American Diabetes Association, DiabetesSisters, Taking Control of Your Diabetes, AstraZeneca Healthcare Foundation, Bristol-Myers Squibb Together on Diabetes Foundation, the National Diabetes Education Program; and UNC has licensed its interest in copyright works to Telcare of a glucose messaging and treatment algorithm for the purposes of commercialization. Dr Donahue reports UNC has licensed its interest in copyright works to Telcare of a glucose messaging and treatment algorithm for the purposes of commercialization. No other disclosures are reported.

**Funding/Support:** Research reported in this publication was funded through a Patient-Centered Outcomes Research Institute Award CE-12-11-4980. Further support was provided by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Award Number UL1TR001111.

**Role of the Funder/Sponsor:** The Patient-Centered Outcomes Research Institute, National Center for Advancing Translational Sciences, and the National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Monitor Trial Group Members:** Stakeholders: Joanne Rinker, MS, RD, CDE, LDN, American Association of Diabetes Educators; April Reese, BSW, MPH NC Diabetes Advisory Council, North Carolina Department of Health and Human Services; Jim Straight, BA, Carolinas American Diabetes Association; Melvin DuBose, DD, Greensboro Community Advisory Board; Michael Pfeifer, MD, MS, Janssen Pharmaceuticals; Nellie Lewis, RN, Patient Advisor; Val Atkinson, UNC Family Medicine Patient Advisory Board; Jan Hutchins, RN, UNC Physicians Network; Paula LeClair, MBA, Telcare Inc. Participating Primary Care Practices and key current or past clinicians and staff included: Knightdale Family Medicine: Robert



Adams, MD, Li Zhou, MD, Leslie Hopkins, MHA, Chad O'Neal, MBA, CMPE; Rex Family Practice of Knightdale: Ananya Sen, MD, Michelle Benton, MD, Matthew Oettinger, MD, Adija Baily, PA-C, Neil Banks, RN; Mebane Primary Care: Paul Tobin, MD, Linda Stiebris, PA, Nancy St. John, MOA, Brandi Glidewell; UNC Family Medicine at Fuquay-Varina (previously Riverbend Family Medicine): Ley Barnett, MD, James Liffbrig, MD, MPH, Joy Vonk, PA, Sharon Goodwin, RN; Orange Family Medical Group: Arthur Axelbank, MD, Jonathan Klein, MD, MHS, Dawn Raymond, FNP, Gayle Taitt, April Schultz, BSH, MPH, RN, CRRN; Chapel Hill Internal Medicine: Whitman Reardon, MD, Janelle Krasovich, MD, LeVonne Powell-Tillman, MD, Brenda Garrett, Diane Bryant Winstead, MOA; Highgate Family Medical Center: Thomas Marsland, MD, MHA, Anthony Rodriguez, MD, Sally Johnson, MD, Sarah Ruff, MD, Tracy Rentner, FNP, Fonda Strickland; UNC Internal Medicine at Weaver Crossing (Previously UNC Internal Medicine at Chapel Hill North): Aaron Miller, MD, Susan Berendzen, MD, Kathryn Parker, RN, Sherry Duncan, CMA, Kelly Moncavage, Celeste Vinson, Pat Holder; Gibbons Family Medicine, Cary, NC: Gregory Gibbons, MD, PhD, Elizabeth Gibbons, MD, Tara Hanaway-Quinlan, PA-C, Jordan Christiansen, PA-C, Penny Stefanick, BEd, Meredith Trudgeon, MHA; UNC Family Medicine: Kevin Tate, MHA, Yvette McMiller, MHA, Lindsey Stortz, RN, Audra Campbell; Carolina Advanced Health: Thomas Warcup, DO, FAOBF, Nikki Hudson, MHA; UNC Family Medicine at Hillsborough: Paul Dunn, FNP, Jessica Weather, MHS, PA-C, Stephanie Foley, MD; Boylan Healthcare: Todd Helton, MD, PhD, Charles Wehbie, MD, Robert Smithson, MD, Joshua Garriga, MD, Don Lee Zust Jr, DO, Janet G. Davis, Lisa Deckard, Amy Monroe, BS, Jodi Walters. Students included: Kamaara Lucas, BA; Rachel Fuchs, MS; Alexa M. Waters, BS; Paul Alvarez, BS; Caroline Grandis, BS; Sarah Kowitz, MPH. Stakeholders and Participating practices were offered compensation for their time, as part of the PCORI Grant. Students received institutional support through summer assistantships.

**Meeting Presentation:** This study was presented at the American Diabetes Association meeting; June 10, 2017; San Diego CA.

**Disclaimer:** The statements presented in this publication are solely the responsibility of the author(s) and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

**Additional Contributions:** We thank the patients who participated in the trial; the staff and clinicians in the practices in which they received their care; Megan Gallegos, MBA, CRA, and Yana Biblin, BA, in the Cecil G. Sheps Center for Health Services Research Business office for their grant management; Darren Dewalt, MD, MPH, UNC-Chapel Hill, Department of Medicine for health literacy tool input. He was not compensated. We also thank Loretta Fearington, BA, and Bill Ross, UNC-Chapel Hill NC TraCS Institute, for their assistance in extracting data from the Carolina Data Warehouse, they were compensated. We also thank Rachael Fuchs, MS, UNC-Chapel Hill, Department of Biostatistics, for generating the randomization

sequences; and our Stakeholders (Supplement 2). She was compensated.

## REFERENCES

- American Diabetes Association. 5. Glycemic targets. *Diabetes Care*. 2016;39(suppl 1):S39-S46.
- Allemann S, Houriet C, Diem P, Stettler C. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. *Curr Med Res Opin*. 2009;25(12):2903-2913.
- Clar C, Barnard K, Cummins E, Royle P, Waugh N. Aberdeen Health Technology Assessment Group. Self-monitoring of blood glucose in type 2 diabetes: systematic review. *Health Technol Assess*. 2010;14(12):1-140.
- Farmer AJ, Perera R, Ward A, et al. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. *BMJ*. 2012;344:e486-e486.
- Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database of Systematic Reviews. <http://online.library.wiley.com/libproxy.lib.unc.edu/doi/10.1002/14651858.CD005060.pub3/full>. Login required. Accessed April 9, 2017.
- Poolsup N, Suksomboon N, Rattanasookchit S. Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients: an update. *Diabetes Technol Ther*. 2009;11(12):775-784.
- Towfigh A, Romanova M, Weinreb JE, et al. Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis. *Am J Manag Care*. 2008;14(7):468-475.
- Wang J, Zgibor J, Matthews JT, Charon-Prochownik D, Sereika SM, Siminerio L. Self-monitoring of blood glucose is associated with problem-solving skills in hyperglycemia and hypoglycemia. *Diabetes Educ*. 2012;38(2):207-218.
- Barnett AH, Krentz AJ, Strojek K, et al. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen: a multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). *Diabetes Obes Metab*. 2008;10(12):1239-1247.
- Durán A, Martín P, Runkle I, et al. Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St Carlos Study, a prospective randomized clinic-based interventional study with parallel groups. *J Diabetes*. 2010;2(3):203-211.
- Guerci B, Drouin P, Grangé V, et al; ASIA Group. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. *Diabetes Metab*. 2003;29(6):587-594.
- Schwedes U, Siebolds M, Mertens G. SMBG Study Group. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. *Diabetes Care*. 2002;25(11):1928-1932.
- Davidson MB, Castellanos M, Kain D, Duran P. The effect of self monitoring of blood glucose concentrations on glycosylated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. *Am J Med*. 2005;118(4):422-425.
- Farmer AJ, Wade AN, French DP, et al. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. *Health Technol Assess*. 2009;13(15):iii-iv, ix-xi, 1-50.
- Kleefstra N, Hortensius J, Logtenberg SJJ, et al. Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC). *Neth J Med*. 2010;68(1):311-316.
- Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. *Acta Diabetol*. 1994;31(4):215-219.
- O'Kane MJ, Bunting B, Copeland M, Coates VE. ESMON study group. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. *BMJ*. 2008;336(7654):1174-1177.
- Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A; Diabetes Glycaemic Education and Monitoring Trial Group. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. *BMJ*. 2008;336(7654):1177-1180.
- Bonomo K, De Salve A, Fiora E, et al. Evaluation of a simple policy for pre- and post-prandial blood glucose self-monitoring in people with type 2 diabetes not on insulin. *Diabetes Res Clin Pract*. 2010;87(2):246-251.
- Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. *Diabetes Care*. 2011;34(2):262-267.
- Fisher L, Polonsky WH, Parkin CG, Jelsovsky Z, Petersen B, Wagner RS. The impact of structured blood glucose testing on attitudes toward self-management among poorly controlled, insulin-naïve patients with type 2 diabetes. *Diabetes Res Clin Pract*. 2012;96(2):149-155.
- Selby JV, Forsythe L, Sox HC. Stakeholder-Driven Comparative Effectiveness Research: An Update From PCORI. *JAMA*. 2015;314(21):2235-2236.
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. *Med Care*. 1992;30(6):473-483.
- Welch GW, Jacobson AM, Polonsky WH. The Problem Areas in Diabetes Scale: an evaluation of its clinical utility. *Diabetes Care*. 1997;20(5):760-766.
- Herschbach P, Duran G, Waadt S, et al. Psychometric properties of the Questionnaire on Stress in Patients with Diabetes-Revised (QSD-R). *Health Psychol*. 1997;16(2):171-174.
- Anderson RM, Fitzgerald JT, Gruppen LD, Funnell MM, Oh MS. The Diabetes Empowerment Scale-Short Form (DES-SF). *Diabetes Care*. 2003;26(5):1641-1642.
- Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. *Diabetes Care*. 2000;23(7):943-950.

28. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. *Diabet Med*. 1990;7(5):445-451.
29. Makoul G, Krupat E, Chang CH. Measuring patient views of physician communication skills: development and testing of the Communication Assessment Tool. *Patient Educ Couns*. 2007;67(3):333-342.
30. Dunnett CW, Tamhane AC. Step-up multiple testing of parameters with unequally correlated estimates. *Biometrics*. 1995;51(1):217-227.
31. Weiss BD, Mays MZ, Martz W, et al. Quick assessment of literacy in primary care: the newest vital sign. *Ann Fam Med*. 2005;3(6):514-522.
32. Choosing Wisely: Society of General Internal Medicine. <http://www.choosingwisely.org/clinician>
- lists/society-general-internal-medicine-daily-home-finger-glucose-testing-type-2-diabetes-mellitus/. Accessed February 10, 2017.
33. American Diabetes Association. 6. Glycemic Targets. *Diabetes Care*. 2017;40(suppl 1):S48-S56.
34. Czupryniak L, Barkai L, Bolgarska S, et al. Self-monitoring of blood glucose in diabetes: from evidence to clinical reality in Central and Eastern Europe—recommendations from the international Central-Eastern European expert group. *Diabetes Technol Ther*. 2014;16(7):460-475.
35. Kesavadev J, Sadikot S, Wangnoo S, et al. Consensus guidelines for glycemic monitoring in type 1/type 2 & GDM. *Diabetes Metab Syndr*. 2014;8(3):187-195.
36. Chomutare T, Fernandez-Luque L, Arсанд E, Hartvigsen G. Features of mobile diabetes applications: review of the literature and analysis of current applications compared against evidence-based guidelines. *J Med Internet Res*. 2011;13(3):e65.
37. Kaufman ND, Woodley PD. Self-management support interventions that are clinically linked and technology enabled: can they successfully prevent and treat diabetes? *J Diabetes Sci Technol*. 2011;5(3):798-803.
38. US Census Bureau. 2009-2013 5-Year American Community Survey. <http://www.census.gov/data/developers/updates/acs-5-yr-summary-available-2009-2013.html>. 2014. Accessed November, 2016.

---

 Editor's Note
 

---

## The Need to Test Strategies Based on Common Sense

Elaine C. Khoong, MD, MS; Joseph S. Ross, MD, MHS

### “You have diabetes.”

In most care settings, this statement still triggers prescription of a glucometer and instruction on how to perform self-monitoring of blood glucose (SMBG). Every 3 months thereafter, patients' glucose logs are reviewed and routine SMBG



Related article [page 920](#)

is encouraged, regardless of patients' risk of hypoglycemia

or severe hyperglycemia, because common sense tells us that patients who proactively manage and monitor their diabetes should achieve better outcomes. In this issue of *JAMA Internal Medicine*, Young and colleagues<sup>1</sup> test this long-held belief, randomizing 450 patients with non-insulin-dependent type 2 diabetes to no SMBG, SMBG, and SMBG with enhanced patient feedback. At 1 year, there were no differences in glycemic control, health-related quality of life, or adverse events (including hypoglycemia frequency, health care utilization,

or insulin initiation). Nearly 75% of patients engaged in routine SMBG prior to enrollment. These results suggest that we can safely advise patients to discontinue, as well as not initiate, SMBG.

This important study was funded by the Patient-Centered Outcomes Research Institute and illustrates how patient-centered clinical research can address clinical problems. The surprising findings make us question the current seemingly common sense-based strategy to encourage routine SMBG. These findings and others<sup>2</sup> support the Choosing Wisely<sup>3</sup> recommendations of the Society of General Internal Medicine and Endocrine Society that discourage frequent blood glucose monitoring among patients with type 2 diabetes. Routine SMBG merits a “less is more” designation because there were no clear benefits accrued, which leaves only possible harms.

**Author Affiliations:** Department of Medicine, University of California, San Francisco (Khoong); Department of Medicine, Section of General Internal Medicine, Yale University School of Medicine, New Haven, Connecticut (Ross); Associate Editor, *JAMA Internal Medicine* (Ross).

**Corresponding Author:** Elaine C. Khoong, MD, MS, Department of Medicine, University of California, San Francisco, 1001 Potrero Avenue, 1M, San Francisco, CA 94110 ([elaine.khoong@ucsf.edu](mailto:elaine.khoong@ucsf.edu)).

**Conflict of Interest Disclosures:** Dr Ross receives research funding through Yale University from Medtronic Inc and the US Food and Drug Administration (FDA) to study issues in postmarket medical device surveillance, from the FDA to

establish the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation, from Johnson & Johnson to develop methods for clinical trial data sharing, from the Centers for Medicare and Medicaid Services to develop measures for public reporting hospital and physician quality, from the Blue Cross Blue Shield Association to advance premarket evidence generation for medical products, and from the Laura and John Arnold Foundation to support the Collaboration on Research Integrity and Transparency at Yale University. No other disclosures are reported.

1. Young LA, Buse JB, Weaver MA, et al; Monitor Trial Group. Glucose self-monitoring in

non-insulin-treated type 2 diabetes in primary care settings: a randomized trial [published online June 10, 2017]. *JAMA Intern Med*. doi:10.1001/jamainternmed.2017.1233

2. Wofford JL, Martin MJ, Campos CL. Eliminating routine glucometer readings in the office setting: correcting a foolish consistency. *JAMA Intern Med*. 2016;176(11):1721-1722. doi:10.1001/jamainternmed.2016.5883

3. ABIM Foundation. Choosing Wisely. <http://www.choosingwisely.org/>. Accessed February 8, 2017.